A drug company says that partial results from a study testing an antibody drug give hints that it may help keep mild to moderately ill COVID-19 patients from needing to be hospitalized, a goal no current coronavirus medicine has been able to meet.
Eli Lilly announced the results Wednesday in a press release, but they have not been published or reviewed by independent scientists.
The drug missed the study’s main goal of reducing the amount of virus patients had after 11 days, except at the middle of three doses being tested. However, most study participants, even those given a placebo treatment, had cleared the virus by then, so that time point now seems too late to judge that potential benefit, the company said.
Other tests suggest the drug was reducing virus sooner, and the results are an encouraging “proof of principle” as this and other studies continue, Lilly said.
The company said it would talk with regulators about possible next steps but that it was too soon to speculate on whether these interim results might lead to any action to allow early use.
